Hemophilia medical therapy

Jump to: navigation, search

Hemophilia Microchapters


Patient Information


Historical Perspective




Differentiating Hemophilia from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemophilia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Hemophilia medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemophilia medical therapy

CDC on Hemophilia medical therapy

Hemophilia medical therapy in the news

Blogs on Hemophilia medical therapy

Directions to Hospitals Treating Hemophilia

Risk calculators and risk factors for Hemophilia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]


Clotting factor replacement is the mainstay of hemophilia treatment. Plasma-derived factor concentrates and recombinant factor concentrates are the two types used in the replacement therapy. Other products used as therapy include desmopressin acetate, antifibrinolytics, and cryoprecipitate. Gene therapy has the potential to change the course of hemophilia therapy and care.

Medical Therapy

Clotting Factor Replacement

  • Clotting factor replacement is the mainstay of hemophilia treatment
  • The two types of clotting factor concentrates used as replacement are:

1. Plasma-derived factor concentrates

2. Recombinant factor concentrates

Complications Clotting Factor Replacement

Other Products

  • The other products used as a part of medical therapy of hemophilia include:

1. Antifibrinolytics

2. Desmopressin acetate

3. Cryoprecipitate

Immune Tolerance Induction

Gene Therapy


  1. 1.0 1.1 Kevane B, O'Connell N (August 2018). "The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A". Transfus. Apher. Sci. 57 (4): 502–506. doi:10.1016/j.transci.2018.07.012. PMID 30107983.
  2. Stonebraker, J. S.; Brooker, M.; Amand, R. E.; Farrugia, A.; Srivastava, A. (2010). "A study of reported factor VIII use around the world". Haemophilia. 16 (1): 33–46. doi:10.1111/j.1365-2516.2009.02131.x. ISSN 1351-8216.
  3. Peyvandi, Flora; Mannucci, Pier M.; Garagiola, Isabella; El-Beshlawy, Amal; Elalfy, Mohsen; Ramanan, Vijay; Eshghi, Peyman; Hanagavadi, Suresh; Varadarajan, Ramabadran; Karimi, Mehran; Manglani, Mamta V.; Ross, Cecil; Young, Guy; Seth, Tulika; Apte, Shashikant; Nayak, Dinesh M.; Santagostino, Elena; Mancuso, Maria Elisa; Sandoval Gonzalez, Adriana C.; Mahlangu, Johnny N.; Bonanad Boix, Santiago; Cerqueira, Monica; Ewing, Nadia P.; Male, Christoph; Owaidah, Tarek; Soto Arellano, Veronica; Kobrinsky, Nathan L.; Majumdar, Suvankar; Perez Garrido, Rosario; Sachdeva, Anupam; Simpson, Mindy; Thomas, Mathew; Zanon, Ezio; Antmen, Bulent; Kavakli, Kaan; Manco-Johnson, Marilyn J.; Martinez, Monica; Marzouka, Esperanza; Mazzucconi, Maria G.; Neme, Daniela; Palomo Bravo, Angeles; Paredes Aguilera, Rogelio; Prezotti, Alessandra; Schmitt, Klaus; Wicklund, Brian M.; Zulfikar, Bulent; Rosendaal, Frits R. (2016). "A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A". New England Journal of Medicine. 374 (21): 2054–2064. doi:10.1056/NEJMoa1516437. ISSN 0028-4793.
  4. Makris, M.; Kessler, C. M. (2017). "SIPPET trial: the answers". Haemophilia. 23 (3): 344–345. doi:10.1111/hae.13239. ISSN 1351-8216.
  5. Fallon, P. G.; Lavin, M.; O'Donnell, J. S. (2018). "SIPPET: insights into factor VIII immunogenicity". Journal of Thrombosis and Haemostasis. 16 (1): 36–38. doi:10.1111/jth.13886. ISSN 1538-7933.
  6. https://www.cdc.gov/ncbddd/hemophilia/treatment.html
  7. https://www.cdc.gov/ncbddd/hemophilia/treatment.html
  8. https://www.nhlbi.nih.gov/health-topics/hemophilia#Treatment
  9. https://www.nhlbi.nih.gov/health-topics/hemophilia#Treatment
  10. 10.0 10.1 10.2 10.3 Watterson C, Beacher N (March 2017). "Preventing perioperative bleeding in patients with inherited bleeding disorders". Evid Based Dent. 18 (1): 28–29. doi:10.1038/sj.ebd.6401226. PMID 28338025.
  11. van Galen KP, Engelen ET, Mauser-Bunschoten EP, van Es RJ, Schutgens RE (December 2015). "Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions". Cochrane Database Syst Rev (12): CD011385. doi:10.1002/14651858.CD011385.pub2. PMID 26704192.
  12. Franchini M, Mannucci PM (July 2013). "Hemophilia A in the third millennium". Blood Rev. 27 (4): 179–84. doi:10.1016/j.blre.2013.06.002. PMID 23815950.
  13. Hews-Girard J, Rydz N, Lee A, Goodyear MD, Poon MC (September 2018). "Desmopressin in non-severe haemophilia A: Test-response and clinical outcomes in a single Canadian centre review". Haemophilia. 24 (5): 720–725. doi:10.1111/hae.13586. PMID 30004154.
  14. 14.0 14.1 Lenk H (November 2014). "Treatment of haemophilia patients in East Germany prior to and after reunification in 1990". Thromb. Res. 134 Suppl 1: S57–60. doi:10.1016/j.thromres.2013.10.018. PMID 24745720.
  15. 15.0 15.1 Jain S, Acharya SS (December 2018). "Management of rare coagulation disorders in 2018". Transfus. Apher. Sci. 57 (6): 705–712. doi:10.1016/j.transci.2018.10.009. PMID 30392819.
  16. Nascimento B, Goodnough LT, Levy JH (December 2014). "Cryoprecipitate therapy". Br J Anaesth. 113 (6): 922–34. doi:10.1093/bja/aeu158. PMC 4627369. PMID 24972790.
  17. Delignat S, Russick J, Gangadharan B, Rayes J, Ing M, Voorberg J, Kaveri SV, Lacroix-Desmazes S (December 2018). "Prevention of the anti-factor VIII memory B-cell response by inhibition of the Bruton's tyrosine kinase in experimental hemophilia A". Haematologica. doi:10.3324/haematol.2018.200279. PMID 30545924.
  18. 18.0 18.1 Nathwani AC, Davidoff AM, Tuddenham E (October 2017). "Gene Therapy for Hemophilia". Hematol. Oncol. Clin. North Am. 31 (5): 853–868. doi:10.1016/j.hoc.2017.06.011. PMID 28895852. Vancouver style error: initials (help)
  19. 19.0 19.1 George LA (December 2017). "Hemophilia gene therapy comes of age". Hematology Am Soc Hematol Educ Program. 2017 (1): 587–594. doi:10.1182/asheducation-2017.1.587. PMC 6142599. PMID 29222308.